Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate

NCT00392405 | Unknown Phase 2

• 1 other identifier: A1
• Study Type: interventional
• Target: 656
• Locations: 1 country
• Sites: 1

Brief Summary

This will be a randomized controlled trial closely following the original protocol in the previous study published in JAMA 2004 by Merten et al. Patients will be randomly assigned to one of two treatment groups. Treatment group A will receive 1cc/kg/hour of 0.9% normal saline at least 2 hours prior to study beginning and will be continued during and for 6 hours post contrast. Treatment group B will receive 3cc/kg of sodium bicarbonate solution for one hour prior to procedure then drip rate will be decreased to 1cc/kg/hour during and for 6 hours post procedure. The sodium bicarbonate solution will be made by adding 3 amps of bicarbonate to 1L of D5W. Patients in both treatment arms weighing \>110kg the initial fluid bolus and drip will be limited to those patients weighing 110kg. In both treatment arms, diuretics will be held before and after contrast administration on the day of the study. BMP will be checked the day of, 24 and 48 hours post contrast administration. The greatest change in all readings will be used for treatment comparisons. Contrast induced nephropathy will be defined as a change in serum creatinine of more than 25% from baseline and/or 0.5mg/dL. Urinary pH will also be measured on first spontaneous void following bolus. Vital signs including blood pressure and oxygen saturation will be documented every 4 hours to monitor patients closely for signs and symptoms of volume overload

Conditions

Contrast Induced Nephropathy

Keywords

Contrast Induced Nephropathy

Outcome Measures

Primary Outcomes (1)

• Development of contrast-induced nephropathy, defined as an increase in serum creatinine of 25% or more within 2 day after administration of contrast

Secondary Outcomes (9)

• change in mean arterial pressure after initial bolus, mmHg

• urine pH after initial bolus

• contrast volume

• change in serum bicarbonate

• change in serum potassium

Interventions

3 amps of sodium bicarbonate mixed in one liter of D5W DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Stage III Chronic Kidney Disease (GFR 30-60ml/min per 1.73m2 calculated by using MDRD equation)
• Inpatients at Norton Community Hospital scheduled to undergo diagnostic CT Scan using contrast between the hours of 7am and 6pm
• + years of age

You may not qualify if:

• Current clinical diagnosis of exacerbated congestive heart failure
• Creatinine \>8 mg/dL
• Change in serum Cre of at least 0.5mg/dL during previous 24hours
• Pre-existing dialysis patient
• Multiple myeloma
• Uncontrolled hypertension (definition: treated SBP \>160mmHg or DBP \>100mmHg
• Exposure to contrast 48 hours prior to study
• Allergy to contrast dye
• Pregnancy
• Patient has received pressor agents, fendolapam, mannitol, or mucomyst at time of study
• Acute myocardial infarction

Sponsors & Collaborators

• Norton Community Hospital: lead

Study Sites (1)

Norton Community Hospital

Norton, Virginia, 24273, United States

Location

Related Publications (2)

• Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328-34. doi: 10.1001/jama.291.19.2328.

  PMID: 15150204 BACKGROUND

• Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006 Jan 26;354(4):379-86. doi: 10.1056/NEJMcp050801. No abstract available.

  PMID: 16436769 BACKGROUND

Study Officials

• Donna S Sanders, DO

  Norton Community Hospital

  PRINCIPAL INVESTIGATOR

• Mathew Cusano, MD

  Norton Community Hospital

  STUDY DIRECTOR

Central Study Contacts

Donna S Sanders, DO

CONTACT

276-708-7021; dsanders_nch@yahoo.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: October 25, 2006
• First Posted: October 26, 2006
• Study Start: November 1, 2006
• Last Updated: October 26, 2006

Record last verified: 2006-10

Locations

US (1)